23andMe Holding Co.
News
One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations
Globe Newswire 23andMe, National Human Genome Research Institute, and Johns Hopkins University conducted collaborative research that studied sickle cell trait in a diverse populationSUNNYVALE, Calif., Sept. 12...\n more…
23andMe to Present Updates on Clinical Immuno-oncology Programs 23ME-00610 and 23ME-01473 at ESMO Congress 2024
Globe Newswire Preliminary data from renal cancer and TMB-H/MSI-H cohorts in the Phase 1/2a clinical trial of 23ME-00610 to be presented Analysis of CD200 as an exploratory tissue-based biomarker associated with...\n more…
Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership Program
Globe Newswire In conjunction with this new offering, 23andMe, Lemonaid Health's parent company, recently launched study focused on the role genetics may play in effectiveness and side effects of GLP-1sSUNNYVALE...\n more…
23andMe Holding Co. (NASDAQ:ME) Shares Sold by Vanguard Group Inc.
Ticker Report Vanguard Group Inc. cut its holdings in shares of 23andMe Holding Co. (NASDAQ:ME - Free Report) by 27.7% during the first quarter, Holdings Channel.com reports. The institutional investor owned...\n more…
Genetic data-rich spit kits were supposed to fuel 23andMe deals. Now the company's exiting drug discovery
BizJournals.com - Nat'l Business News Genetic testing company 23andMe is eliminating its drug discovery unit, cutting 30 jobs in the process. Here's why\n more…
23andMe Holding Co. (ME) Q1 2025 Earnings Call Transcript
Seeking Alpha: Transcripts 23andMe Holding Co. (ME) Q1 2025 Earnings Call Transcript...\n more…